Low gradient and LV Dysfunction: TAVI or not?

Original Title: Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. Reference: Baron SJ et al. J Am Coll Cardiol. 2016;67:2349-2358.   Low aortic valve gradient and left ventricular dysfunction are frequent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVI) but only low aortic valve<a href="https://solaci.org/en/2016/06/02/low-gradient-and-lv-dysfunction-tavi-or-not/" title="Read more" >...</a>

Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis. Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).   Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and<a href="https://solaci.org/en/2016/05/30/post-tavi-pacemaker-implantation-does-not-increase-mortality/" title="Read more" >...</a>

TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a<a href="https://solaci.org/en/2016/05/20/triguard-neuroprotection-device-during-tavi/" title="Read more" >...</a>

TAVI in Low-Flow / Low-Gradient

Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a<a href="https://solaci.org/en/2016/04/14/tavi-in-low-flow-low-gradient/" title="Read more" >...</a>

TAVI: Good Outcomes with Intermediate Risk

Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence<a href="https://solaci.org/en/2016/04/13/tavi-good-outcomes-with-intermediate-risk/" title="Read more" >...</a>

TAVI in ≥90 year old patients: as beneficial as in younger patients

Original Title: Should Transcatheter Aortic valve replacement Be Performed in Nonagenarians? Insights from the STS/ACC TVT Registry. Reference: Mani Arsalan et al. J Am Coll Cardiol. 2016 Mar 29;67(12):1387-95. Courtesy of Dr. Carlos Fava The benefit of the transcatheter aortic valve replacement (TAVI) has already been shown in the general population undergoing this procedure. The number<a href="https://solaci.org/en/2016/04/12/tavi-in-%e2%89%a590-year-old-patients-as-beneficial-as-in-younger-patients/" title="Read more" >...</a>

New York TAVR Registry: Trends in use and mortality at one year

Original Title: Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis2011 to 2012. Reference:Hannan EL et al. J Am CollCardiolIntv. 2016;9(6):578-585. Courtesy of Dr. Agustín Vecchia It’s been only 14 years sinceCribierperformed the first transcatheter valve replacement. Today, during 2016, 100,000 patients are expected to<a href="https://solaci.org/en/2016/04/08/new-york-tavr-registry-trends-in-use-and-mortality-at-one-year/" title="Read more" >...</a>

PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients. In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis. In-hospital<a href="https://solaci.org/en/2016/04/08/partner-1-in-90-year-old-patients-tavi-and-the-age-paradox/" title="Read more" >...</a>

Atrial Fibrillation: Important Impact on TAVI

Original Title: Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial. Reference: Angelo B. Biviano et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002766. Courtesy of Dr. Carlos Fava. The conversion to atrial fibrillation (AF) in the context of transcatheter aortic valve replacement<a href="https://solaci.org/en/2016/03/04/atrial-fibrillation-important-impact-on-tavi/" title="Read more" >...</a>

Comparing Computed Tomography vs. Angiography to Assess Transfemoral Access for TAVI

Original Title: Transfemoral Access Assessment for Transcatheter Aortic Valve Replacement Evidence Based Application of Computed Tomography over Invasive Angiography. Reference: Circ Cardiovas Imaging 2015 DOI:10.1161/CIRCIMAGING.114.0011995. Courtesy of Dr. Guillermo Migliaro Transfemoral access for TAVI was introduced in 2006 and is considered first choice. Vascular complications (VCs) are important events that correlate to increased mortality. According to the<a href="https://solaci.org/en/2016/01/18/comparing-computed-tomography-vs-angiography-to-assess-transfemoral-access-for-tavi/" title="Read more" >...</a>